Zydus Cadila gets USFDA approval to market generic schizophrenia drug Perphenazine

Zydus Cadila said it has 284 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of its filing process in the financial year 2003-2004.

FP Trending April 08, 2020 13:21:11 IST
Zydus Cadila gets USFDA approval to market generic schizophrenia drug Perphenazine

Pharma company Zydus Cadila has said it has received final approval from United States Food and Drug Administration (USFDA) to market generic Perphenazine tablets, used in the treatment of schizophrenia.

The drug is also used for the control of severe nausea and vomiting in adults.

USFDA has given its final nod to the company to market Perphenazine tablets USP in the strengths of 2 mg, 4 mg, 8 mg and 16 mg, Zydus Cadila said in a statement.

Zydus Cadila gets USFDA approval to market generic schizophrenia drug Perphenazine

Representative image. Image source: Pixabay

The USFDA is tasked with promoting public health through the control and supervision of several verticals including over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals and others.

“The drug will be manufactured at the group’s formulation manufacturing facility at Baddi [,” the statement added.

Zydus Cadila said it has 284 approvals and has so far filed over 386 abbreviated new drug applications (ANDAs) since the commencement of its filing process in the financial year 2003-2004.

On Tuesday, the pharma major announced on Twitter that it is producing Hydroxychloroquine, in large quantities to be used in the “treatment of coronavirus .” The company also said that it is working on developing a vaccine which will be a long term solution for COVID-19 .

India on Tuesday decided to partially lift the ban on Hydroxychloroquine export, news agency PTI reported quoting officials.

US President Donald Trump had requested Prime Minister Narendra Modi to release the amount of Hydroxychloroquine ordered by the US after India on 25 March banned the export of the drug.

Updated Date:

also read

India records 8,774 new COVID-19 cases, 621 deaths; at 98.34% recovery rate highest since March last year
India

India records 8,774 new COVID-19 cases, 621 deaths; at 98.34% recovery rate highest since March last year

So far 121.94 crore COVID-19 vaccine doses have been administered across the country under the nationwide vaccination drive

COVID-19: India registers 8,488 new cases, lowest in 538 days; 249 fresh fatalities
India

COVID-19: India registers 8,488 new cases, lowest in 538 days; 249 fresh fatalities

The active cases comprise 0.34 percent of the total infections, the lowest since March 2020, while the national recovery rate is at 98.31 percent, the highest since March 2020, the health ministry said

COVID-19: India adds 9,283 new infections, 437 deaths; active cases lowest in 537 days
India

COVID-19: India adds 9,283 new infections, 437 deaths; active cases lowest in 537 days

The daily rise in new coronavirus infections has been below 20,000 for 47 straight days and less than 50,000 daily new cases have been reported for 150 consecutive days now